Danish Aerospace Company to build prototype of exercise equipment for the Moon and eventually Mars
COMPANY ANNOUNCEMENT
Odense, May 28, 2025
Company Announcement no. 61 – 28.05.2025
Danish Aerospace Company to build prototype of exercise equipment for the Moon and eventually MarsDanish Aerospace Company A/SCVR no.: 12424248
Danish Aerospace Company A/S (DAC), Odense, has today signed a contract with the European Space Agency ESA to develop and build a prototype of a new exercise device that can be used on the Lunar Gateway space station orbiting the Moon and eventually for human missions to Mars.
The six-month contract entails the development of a prototype of exercise technology to meet the standards of Lunar Gateway.
The new prototype will also include a new form of exercise - jumping - to help strengthen the astronauts' bones, muscles, and cardiovascular system while they are in space.
The Gateway Exercise Equipment study contract runs for approximately 6 months and has a total value for DAC of approximately EUR 580,000. (DKK 4.3 million).
The contract does not change the company's previously announced expectations for 2025.
The Lunar Gateway is a new space station that NASA, ESA, Japan and Canada have agreed to develop. NASA's current plans envision launch and beginning initial operations of the Lunar Gateway in about 2028. The Gateway will orbit the Moon, where it will be visited by astronauts for 30 to 90 days at a time.
This represents a big step forward for DAC, and the first time the company is seriously looking at moving further into space with its exercise equipment, after having supplied ESA and NASA with exercise- and medical monitoring equipment for more than three decades for the Space Shuttle and the International Space Station (ISS) programs.
Amentum Clean Energy from England will participate in the project as a subcontractor. Over the next six months, DAC's sophisticated exercise technology will be refined further so the new exercise device can meet the unique requirements of the Lunar Gateway. The new prototype will also include a new form of exercise - jumping - to help strengthen the astronauts' bones, muscles, and cardiovascular system while they are in space.
Amentum Clean Energy's contribution to the prototype study involves development of a vibration damping system that ensures vibrations from the astronauts' exercise do not propagate to the Lunar Gateway space station and disrupt systems and other research on board.
"We are extremely proud that ESA has chosen Danish Aerospace Company to develop a prototype of the exercise equipment for the Lunar Gateway. This shows our extensive experience in this area, but it also offers a lot of exciting new challenges. The exercise equipment must be even more reliable than before, because it is much further away from home. For example, the electronics in the equipment must be able to withstand the much higher background radiation so far from Earth and still function, and the HALO module, where the astronauts will exercise, is much smaller than the modules on the ISS; so the exercise device we develop must be optimized even more. We are very much looking forward to contributing to this fascinating new area", says Thomas A. E. Andersen, CEO, DAC.
The Gateway Exercise Equipment study contract runs for approximately 6 months and has a total value for DAC of approximately EUR 580,000. (DKK 4.3 million).
For further information, please contact:
Danish Aerospace Company A/S:CEO Thomas A.E. AndersenCell: +45 40 29 41 62
Certified Adviser:Baker Tilly Corporate Finance P/S Poul Bundgaards Vej 1, 1.DK-2500 Valby Tel.: +45 33 45 10 00 www.bakertilly.dk
About Danish Aerospace Company A/S:
Danish Aerospace Company (DAC) is a high-tech company operating in the area of advanced medical instrumentation and other engineering fields primarily within space applications.
Our products are based on many years of specialized research and development. These consist of developing, integrating, and applying new as well as established medical technologies to the challenges of functioning and remaining reliable in space. These products and services bring the potential of space research and experience from space operations down to Earth for the benefit of all mankind.
Danish Aerospace Company employs engineers and technicians who deliver full engineering, production and technical services for our customers. We specialize in customer specific design, development, manufacturing, certification, maintenance, testing, and operations.
The company has developed five generations of respiratory equipment for spaceflight, ergometers for astronauts, countermeasures, adapted several commercial medical equipment for spaceflight and has participated in the development of the minus eighty-degree Celsius freezers.
The Company's quality system is certified in obligation to BS EN ISO 9001:2015, BS EN 9100:2018 technical equivalent to AS9100D that is the acknowledged standard in the area.
Note: This is a translation of the corresponding Company Announcement in Danish. In case of discrepancies between the Danish wording and the English translation, the Danish wording prevails.
www.DanishAerospace.comSign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
UnitedHealth Group has an unusual new CEO pay package
In today's CEO Daily: Geoff Colvin on UnitedHealth Group's controversial CEO pay package. The big story: U.S.-China trade talks stall. The markets: Mixed in the face of tariff uncertainty. Analyst notes from UBS, Deutsche Bank, and Macquarie. Plus: All the news and watercooler chat from Fortune. Good morning. Geoff Colvin writing today. It has been quite a year for UnitedHealth Group (UHG)—and now in addition to myriad other troubles, UHG is adding a controversial CEO pay package to its plate. The giant healthcare concern has seen an unprecedented loss of value recently. UHG is America's largest healthcare company, No. 3 on the Fortune 500, but in April it reported a surprisingly terrible first-quarter performance. The stock price plunged, then kept plunging for weeks. CEO Andrew Witty resigned abruptly for unspecified personal reasons, and the board chairman, Stephen Hemsley, took over as CEO. Hemsley, who turns 73 in June, will be trying to rescue the colossus he helped build as CEO from 2006 to 2017. While investors might have expected he would hold the job only until a new CEO is found, Hemsley and the board have other ideas. The highly unusual pay package they created for him shows how. He will get a base salary of $1 million a year—big money but actually below the usual salary for CEOs of such large companies. More importantly, he would get a one-time $60 million grant of stock options, with a twist: He would get the payoff only if he remains CEO for three years. He would get no other stock-based awards in that period. Shareholders will get to vote on that unconventional pay plan at UHG's June 2 annual meeting. Institutional Shareholder Services (ISS), the largest firm that advises major shareholders on how to vote, advises they vote No. They cite a lack of performance criteria and the fact that the stock is so beaten down he might get a windfall for a mere share price rebound. UHG struck back, sending shareholders an explanation of what ISS allegedly missed and why they should vote for Hemsley's pay package. Bottom line, Hemsley and UHG will probably get the pay package they negotiated. ISS's recommendations are taken seriously, but shareholders usually vote in favor of management. Even if UHG loses the vote, which companies must hold by law, the result is non-binding and advisory only; the board of directors could simply ignore the shareholders' wishes. In addition, UHG notes that ISS's main competitor, Glass Lewis, is recommending shareholders vote in favor of Hemsley's pay package. Regardless of the outcome, the contested vote will be significant. It will raise the already high stakes for UHG, its directors, and for Hemsley. More news CEO Daily via Diane Brady at This story was originally featured on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
2 Top Stocks to Buy With Less Than $100
Novo Nordisk should perform well thanks to new leadership and a strong underlying business. Exelixis' main oncology franchise is safe for now even as it seeks to develop newer products. 10 stocks we like better than Novo Nordisk › When investing on a budget, buying fractional shares of top companies is one option. Another is to find stocks with relatively affordable price tags per share. Although it's sometimes the case that the most attractive companies quickly draw attention, which bids up their share prices, it's still possible to find promising stocks for well under $100. Two great options right now are Novo Nordisk (NYSE: NVO) and Exelixis (NASDAQ: EXEL). Here's why these healthcare companies are worth investing in today. Novo Nordisk had been flying high since the beginning of the decade, until it ran into significant clinical and regulatory headwinds last year. Its challenges eventually came to a boiling point and the company parted ways with its longtime CEO, Lars Fruergaard Jørgensen, a decision it announced in mid-May. It's worth noting that Jørgensen led Novo Nordisk through a period of rapid clinical advancements, particularly within its GLP-1 segment. Novo Nordisk's top medicines, Wegovy for weight management and Ozempic for diabetes, continue to deliver excellent results. Jørgensen leaves a solid foundation for the next head of the company to build upon. Given Novo Nordisk's lineup, pipeline, and track record, the stock is likely to recover eventually. Here's one reason why. Despite recent challenges, Novo Nordisk's revenue continues to grow faster than that of almost every similarly sized pharmaceutical company. In the first quarter, net sales totaled 78.1 billion Danish kroner ($11.9 billion), a 19% increase compared to the same period last year. And on the bottom line, earnings per share were 6.53 DKK ($1), up 15% year over year. Meanwhile, Novo Nordisk should continue making moves to remain competitive in the fast-growing anti-obesity market, despite incurring some losses recently to its biggest rival, Eli Lilly. Novo Nordisk recently submitted an application to U.S. regulators requesting approval for an oral version of semaglutide, the active ingredient in Wegovy and Ozempic. Current GLP-1 therapies are typically administered by injection. Novo Nordisk also has several early-stage assets in this field, including a potential triple agonist -- a GLP-1 medicine that also mimics the action of two other gut hormones. Elsewhere, the FDA (U.S. Food and Drug Administration) accepted the company's regulatory application for Wegovy in treating metabolic dysfunction-associated steatohepatitis (MASH) and granted it priority review; it's also under review by regulatory authorities for this indication in Europe. There is only one FDA-approved medicine for MASH, despite the millions of patients affected and the condition's growing prevalence. Lastly, Novo Nordisk is making progress across its pipeline, including in other therapeutic areas, such as Alzheimer's disease, where it has upcoming data readouts. Recent headwinds notwithstanding, the company remains well- positioned to lead in diabetes and obesity care for the long term, while also making strides in other areas. The stock could still deliver superior returns to patient investors. And with shares trading for just under $71 each, $100 can get you one of them. Exelixis is an oncology specialist; its most important medicine, Cabometyx, treats some forms of liver and kidney cancer. Some investors have long been worried about Exelixis' overreliance on this drug, and with good reason. In the first quarter, Exelixis' revenue came in at $555.4 million, up 30% year over year; Cabometyx's sales came in at $510.9 million. If something were to happen to this medicine -- like generic competition -- it would be a disaster for the company. Fortunately, Exelixis fended off this threat last year with a significant win in a legal battle against a generic-drug manufacturer, which should keep its cheaper competitor off the market until 2030. Still, Exelixis has continued to grind out indications for its crown jewel. One of the latest was in treating metastatic, well-differentiated pancreatic neuroendocrine tumors, a nod it received in March. Cabometyx has long been one of the top-prescribed cancer medicines of its kind in renal cell carcinoma (kidney cancer), and additional indications have helped it continue to grow its sales. Exelixis should maintain that momentum through the end of the decade. Meanwhile, it's developing other cancer medicines. It tends to target areas of the field with high unmet need, such as metastatic colorectal cancer. Despite being the second leading cause of cancer death worldwide, colorectal cancer is highly treatable when caught early -- but once it has metastasized, five-year survival rates drop. Exelixis is developing zanzalintinib to address this problem. The medicine is being tested in other clinical trials as well. Exelixis' revenue and earnings should maintain a solid upward trajectory as it secures more clinical and regulatory wins. That's how the stock can deliver strong returns. Shares are trading for about $43, so you can grab two of them with $100. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,761!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $826,263!* Now, it's worth noting Stock Advisor's total average return is 978% — a market-crushing outperformance compared to 170% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Prosper Junior Bakiny has positions in Eli Lilly, Exelixis, and Novo Nordisk. The Motley Fool has positions in and recommends Exelixis. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Top Stocks to Buy With Less Than $100 was originally published by The Motley Fool
Yahoo
2 hours ago
- Yahoo
At troubled UnitedHealth Group, a highly unusual pay package—potentially worth $60 million to its boomerang CEO—heads to a June vote
Will UnitedHealth Group's new CEO get the hefty pay package the board wants to give him? That eight-figure question rises amid UHG's unprecedented loss of value in the past several weeks. UHG is America's largest health care company, No. 3 on the Fortune 500, but in April it reported surprisingly terrible first-quarter performance. The stock price plunged, then kept plunging for weeks. CEO Andrew Witty resigned abruptly for unspecified personal reasons, and the board chairman, Stephen Hemsley, took over as CEO. Hemsley, who turns 73 in June, will be trying to rescue the colossus he helped build as CEO from 2006 to 2017. While investors might have expected he would hold the job only until the board of directors finds a new CEO, Hemsley and the board have other ideas. The highly unusual pay package they created for Hemsley shows how. He will get a base salary of $1 million a year—big money but actually below the usual salary for CEOs of such large companies. More important, he would get a one-time $60 million grant of stock options, with a twist: He would get the payoff only if he remains CEO for three years. He would get no other stock-based awards in that period. Shareholders will get to vote on that unconventional pay plan at UHG's June 2 annual meeting. Institutional Shareholder Services, the largest firm that advises major shareholders on how to vote, advises they vote no. ISS sees multiple problems with Hemsley's pay package. Such big, front-loaded, multiyear awards 'limit the board's ability to meaningfully adjust future pay opportunities,' ISS says. In addition, Hemsley didn't need to meet any performance criteria to earn the mammoth stock option award; he got the whole thing on day one. Hemsley also got the award just as bad news was pounding the share price down to its lowest in nearly five years, meaning he might get 'a windfall' for a mere 'rebound in the share price.' Combine those factors, says ISS, and a no vote 'is now warranted.' UHG struck back, sending shareholders an explanation of what ISS allegedly missed and why they should vote for Hemsley's pay package. The company's central point: 'The award only has value if and to the extent shareholder value is created.' As for ISS's 'windfall' argument, UHG stated that 'in reality all [underlined and bold in the UHG document] shareholders would gain from increases in the company's stock price relative to current levels.' Who's likely to win this vote? Bottom line, Hemsley and UHG will probably get the pay package they negotiated. ISS's recommendations are taken seriously, but shareholders usually vote in favor of management. Even if UHG loses the shareholder vote on pay, which companies must hold by law, the result is nonbinding and advisory only; the board of directors could simply ignore the shareholders' wishes. In addition, UHG notes that ISS's main competitor, Glass Lewis, is recommending shareholders vote in favor of Hemsley's pay package. 'Upon a cursory glance,' it tells its clients, '[Hemsley's] annualized compensation is not excessive.' Regardless of the outcome, the contested vote will be significant. It will raise the already high stakes for UHG, its directors, and Hemsley. Three years from now, success in the face of opposition would look all the more heroic—and failure would be all the more bitter. This story was originally featured on Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
